Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study)

Biological & Pharmaceutical Bulletin
Tatsuya MorimotoKoji Hasegawa

Abstract

Statins, 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, are potential drugs for chronic heart failure treatment in clinical studies. However, there may be differences in the effects on heart failure between lipophilic and hydrophilic statins. In this study, we investigated whether hydrophilic rosuvastatin (RSV) and lipophilic pitavastatin (PTV) exert different effects on the left ventricular diastolic function. Subjects were hypercholesterolemia patients with left ventricular diastolic dysfunction. This was an open-label, randomized, parallel, comparative, prospective study. The subjects received treatment with RSV or PTV for 24 weeks, and their low density lipoprotein (LDL)-cholesterol levels were controlled by these statins according to the guideline. The primary endpoint was defined as the change in left ventricle (LV) diastolic function (E/E') estimated by echocardiography, and the secondary endpoint was the plasma B-type natriuretic peptide (BNP) level. No serious adverse effects were observed during the entire study period in any patient, nor were there any significant differences in changes in the body mass index, blood pressure, or heart rate. Statin treatment did not significantly alter the primary endpoint...Continue Reading

References

Oct 1, 1993·Journal of the American College of Cardiology·K K HoD Levy
Nov 24, 1999·Clinical and Experimental Pharmacology & Physiology·J D LuoX Chen
Aug 10, 2000·European Journal of Heart Failure·J G ClelandJ Taylor
Jul 20, 2002·The American Journal of Cardiology·Thomas J WangRamachandran S Vasan
Mar 12, 2003·Circulation·J Malcolm O ArnoldUNKNOWN HOPE Investigators
Feb 11, 2004·Circulation·Thomas J WangRamachandran S Vasan
Feb 13, 2004·The New England Journal of Medicine·Thomas J WangRamachandran S Vasan
Apr 28, 2004·The American Journal of Cardiology·Dariush MozaffarianWayne C Levy
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Nov 7, 2007·The New England Journal of Medicine·John KjekshusUNKNOWN CORONA Group
Sep 1, 2009·European Heart Journal·Aldo P MaggioniUNKNOWN GISSI-HF Investigators
Mar 18, 2010·Nature Reviews. Cardiology·W H Wilson Tang, Gary S Francis
Jul 2, 2011·Expert Reviews in Molecular Medicine·Karen E Porter, Neil A Turner
Aug 20, 2011·International Journal of Clinical Practice·N Verma, V M Figueredo
Mar 19, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TakanoUNKNOWN PEARL Study Investigators
Mar 21, 2013·BMJ : British Medical Journal·Colin R DormuthUNKNOWN Canadian Network for Observational Drug Effect Studies
Sep 12, 2013·Pharmacology & Therapeutics·Dimitris TousoulisChristodoulos Stefanadis
Dec 3, 2014·Clinical Biochemistry·Andrew C Don-Wauchope, Robert S McKelvie

❮ Previous
Next ❯

Citations

Oct 19, 2016·International Journal of Cardiology·Yusuke MiyazakiTatsuya Morimoto
Jan 6, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Rehab WeridaNaglaa F Khedr
Dec 3, 2021·International Heart Journal·Yasufumi KatanasakaTatsuya Morimoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved